Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 9:59 PM ET


Company Overview of Enanta Pharmaceuticals, Inc.

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant...

500 Arsenal Street

Watertown, MA 02472

United States

Founded in 1995

52 Employees





Key Executives for Enanta Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 59
Total Annual Compensation: $751.8K
Chief Financial Officer and Senior Vice President of Finance & Administration
Age: 60
Total Annual Compensation: $440.3K
Chief Scientific Officer and Senior Vice President of Research & Development
Age: 63
Total Annual Compensation: $514.1K
Compensation as of Fiscal Year 2014.

Enanta Pharmaceuticals, Inc. Key Developments

Enanta Announces Approval of AbbVie's Viekirax in Japan for Chronic Hepatitis C

Enanta Pharmaceuticals, Inc., (ENTA) announced the approval of AbbVie's (ABBV) Viekirax in Japan for the treatment of genotype 1 chronic hepatitis C, and liver diseases such as compensated cirrhosis. It will be a interferon-free and ribavirin-free treatment option for adult patients. Viekirax consists of a two direct-acting antiviral, oral, fixed-dose combination of protease inhibitor paritaprevir/ritonavir with ombitasvir, dosed once daily for 12 weeks. Approximately 1.5 to 2 million people in Japan is living with HCV. Genotype 1 is the most common HCV genotype with 60% to 70% of patients infected and, of those, about 95% are infected with the genotype 1b (GT1b) sub-type. Upon the approval from Japanese Ministry of Health, Labour and Welfare, Enanta expects to earn and receive a $30 million milestone payment in the quarter ending December 31, 2015. AbbVie is responsible for all worldwide development and commercialization of Viekirax and other HCV treatment regimens containing paritaprevir. The approval is supported by the Phase 3 GIFT-I study.

Enanta Pharmaceuticals, Inc. Approves Amendment to Bylaws

On August 14, 2015, and effective as of such date, the Board of Directors of Enanta Pharmaceuticals, Inc. amended and restated the company's bylaws primarily (i) to include an exclusive forum bylaw to make the courts in Delaware the exclusive forum for specified legal claims, including disputes with Enanta stockholders and beneficial owners of Enanta common stock and (ii) to require additional information to be disclosed by stockholders proposing director nominees or any other proposal to be brought before a meeting of Enanta stockholders.

Enanta Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Provides Royalties Guidance for the Fourth Quarter Ending September 30, 2015

Enanta Pharmaceuticals, Inc. announced consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenue of $11,599,000 compared to $42,051,000 a year ago. Income from operations was $1,703,000 compared to $34,895,000 a year ago. Income before income taxes was $1,990,000 compared to $34,931,000 a year ago. Net income was $2,418,000 or $0.13 per basic and diluted share compared to $50,053,000 or $2.61 per basic and diluted share a year ago. For the nine months, the company reported revenue of $146,464,000 compared to $45,104,000 a year ago. Income from operations was $120,474,000 compared to $24,311,000 a year ago. Income before income taxes was $121,272,000 compared to $24,358,000 a year ago. Net income was $73,180,000 or $3.80 per basic and diluted share compared to $39,480,000 or $2.06 per basic and diluted share a year ago. The company expects its royalties in the quarter ending September 30, 2015 to continue to be approximately 3% of such sales.

Similar Private Companies By Industry

Company Name Region
Cytocom, Inc. United States
Elan Pharmaceutical Investments Ltd. United States
N. American Chem. Corp. United States
ChromBA, Inc. United States
Ciphergen Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enanta Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at